CliffBio
small molecule

AZMIRO

TESTOSTERONE CYPIONATE

Loss of exclusivityMarch 2039latest FDA-listed patent expiry
CompanyAzurity Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameAZMIRO
Active ingredientTESTOSTERONE CYPIONATE
Strength200MG/ML (200MG/ML)
Dosage formSOLUTION
RouteINTRAMUSCULAR
ModalitySmall molecule
FDA approvalJune 2022
Marketing statusRX

Listed patents

PatentExpiresType
12138271March 2039product
11642355March 2039product
11311554March 2039product

More from Azurity Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

AZMIRO patent cliff — loss of exclusivity March 2039 | CliffBio